Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Email
Tweet
Jan de Jong, PhD (he/him/his)
VP Clinical Pharmacology
Immuneering Corporation
Poster(s):
(W-019) Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
Wednesday, November 13, 2024
7:00 AM – 1:45 PM
MST
Email Jan
